Zacks Investment Research
03 Aug 2026, 23:46 UTC · 1h ago
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
03 Aug 2026, 23:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
CRISPR Therapeutics reported quarterly revenues of $10.18 million, surpassing consensus estimates by 37.28% and significantly increasing from $0.89 million a year ago. — A massive year-over-year revenue jump and a significant beat on estimates suggest strong commercial traction or milestone achievements.
+0.60CRISPR Therapeutics reported a quarterly loss of $0.94 per share, which beat the Zacks Consensus Estimate of a $1.10 loss. — Beating earnings estimates (narrower loss than expected) is generally positive, though the company remains unprofitable.
+0.30CRISPR Therapeutics shares have declined approximately 8.5% year-to-date, underperforming the S&P 500's 9.4% gain. — Reflects ongoing negative sentiment and relative weakness in the stock's price action despite the current earnings beat.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company beat both earnings and revenue estimates for the quarter.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
